FABP5 Inhibition against PTEN-Mutant Therapy Resistant Prostate Cancer
Cancers · 21.12.2023 · 16 (1) · 60
DOI: 10.3390/cancers16010060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 21.12.2023. Verfasst von Manojit M Swamynathan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH.
Abstract (Originalsprache)
Resistance to standard of care taxane and androgen deprivation therapy (ADT) causes the vast majority of prostate cancer (PC) deaths worldwide. We have developed RapidCaP, an autochthonous genetically engineered mouse model of PC. It is driven by the loss of PTEN and p53, the most common driver events in PC patients with life-threatening diseases. As in human ADT, surgical castration of RapidCaP animals invariably results in disease relapse and death from the metastatic disease burden. Fatty Acid Binding Proteins (FABPs) are a large family of signaling lipid carriers. They have been suggested as drivers of multiple cancer types. Here we combine analysis of primary cancer cells from RapidCaP (RCaP cells) with large-scale patient datasets to show that among the 10 FABP paralogs, FABP5 is the PC-relevant target. Next, we show that RCaP cells are uniquely insensitive to both ADT and taxane treatment compared to a panel of human PC cell lines. Yet, they share an exquisite sensitivity to the small-molecule FABP5 inhibitor SBFI-103. We show that SBFI-103 is well tolerated and can strongly eliminate RCaP tumor cells in vivo. This provides a pre-clinical platform to fight incurable PC and suggests an important role for FABP5 in PTEN-deficient PC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
- Department of Molecular and Cell Biology, Stony Brook University, Stony Brook, NY 11794, USA.
- The Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Department of Anesthesiology, Stony Brook University, Stony Brook, NY 11794, USA.
- Department of Chemistry, Stony Brook University, Stony Brook, NY 11794, USA.
- Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
ORCID-Profile: Manojit M Swamynathan, Grinu Mathew, Hehe Wang, Michael Giarrizzo, Sarah D Diermeier, Iwao Ojima, Agnieszka B Bialkowska, Lloyd C Trotman
Förderung
- NCI NIH HHS
- NIH HHS
- NIH
- CSHL Cancer Center Support
Zitieren
APA
Swamynathan, M. M., Mathew, G., Aziz, A., Gordon, C., Hillowe, A., Wang, H., Jhaveri, A., Kendall, J., Cox, H., Giarrizzo, M., Azabdaftari, G., Rizzo, R. C., Diermeier, S. D., Ojima, I., Bialkowska, A. B., Kaczocha, M., & Trotman, L. C. (2023). FABP5 Inhibition against PTEN-Mutant Therapy Resistant Prostate Cancer. Cancers, 16(1), 60. https://doi.org/10.3390/cancers16010060
Vancouver
Swamynathan MM, Mathew G, Aziz A, Gordon C, Hillowe A, Wang H, et al. FABP5 Inhibition against PTEN-Mutant Therapy Resistant Prostate Cancer. Cancers. 2023;16(1):60. doi:10.3390/cancers16010060
BibTeX
@article{Swamynathan2023,
author = {Swamynathan, Manojit M and Mathew, Grinu and Aziz, Andrei and Gordon, Chris and Hillowe, Andrew and Wang, Hehe and Jhaveri, Aashna and Kendall, Jude and Cox, Hilary and Giarrizzo, Michael and Azabdaftari, Gissou and Rizzo, Robert C and Diermeier, Sarah D and Ojima, Iwao and Bialkowska, Agnieszka B and Kaczocha, Martin and Trotman, Lloyd C},
title = {FABP5 Inhibition against PTEN-Mutant Therapy Resistant Prostate Cancer},
journal = {Cancers},
year = {2023},
volume = {16},
number = {1},
pages = {60},
doi = {10.3390/cancers16010060}
}
EUVIMED